Skip to main content

Table 1 Characteristic of the patients

From: Gal9/Tim-3 expression level is higher in AML patients who fail chemotherapy

  Disease Response
Complete Remission CR Treatment Failure TF
Patient Characteristics Number (%) Number (%)
 Total patients enrolled 16 10
Female 6 (37%) 8 (80%)
Median Age (years, range) 61 (35–75) 62 (38–74)
Disease State on enrollment*  
 Untreated AML 12 (80%) 2 (22%)
 Relapse/refractory AML 3 (20%) 7 (78%)
Initial AML diagnosis*   
 De Novo AML 8 (53%) 5 (55%)
 Secondary AML after MDS 7 (47%) 4 (45%)
Acquired Mutation Status*   
 FLT3 3 (20%) NMP1 mutated 2 (22%) NMP1 mutated
 CEPBA 1 (6%) 2 (22%)
 NMP1 5 (34%) 1 (11%)
Blast (CD34+)   
 Median 9.90% 48.90%
 Range 4.5–89.7 7.9–76.6
  1. * CR pts. = 15 TF* pts. = 9